The increase in price target from $390 to $400 by Oppenheimer suggests a positive outlook on HCA Healthcare's future performance. The 'Outperform' rating indicates that the analyst expects HCA to perform better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.